Successful treatment of refractory cutaneous protothecosis with MAT2203, an oral lipid nanocrystal formulation of amphotericin B

Joseph Pechacek,Monica M Schmitt,Elise M N Ferrè,Taura Webb,Joel Goldberg,Sabina Pathan,Camilia Banerjee,Princess Barber,Thomas DiMaggio,Anne Quinn,Theresa Matkovits,Leslie Castelo-Soccio,Veronique Nussenblatt,Michail S Lionakis
DOI: https://doi.org/10.1093/ofid/ofae428
2024-07-18
Open Forum Infectious Diseases
Abstract:Abstract Prototheca wickerhamii is a rare cause of cutaneous and systemic infection which requires long treatment courses with potentially toxic medications. We describe a patient with cutaneous protothecosis refractory to triazole monotherapy who experienced clinical and radiographic improvement with the novel oral lipid nanocrystal formulation of amphotericin B without experiencing toxicity.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?